4 Top Dividend Stocks Yielding 4% or More to Buy Right Now for Passive Income

PepsiCo, McCormick, Hormel, and Clorox face shifting consumer preferences, budget pressure, and rising costs, but the article argues their dividend histories and yields—4.1% to 5.7%, versus roughly 1% for the S&P 500—make them attractive to long-term investors. PepsiCo and McCormick reported Q3 2026 organic sales growth of 3.1% and 1.9%, respectively; Clorox projects fiscal 2027 sales growth of up to 14% and organic growth of up to 4.5%, aided by an acquisition. McCormick’s planned Unilever food-business acquisition and Clorox’s recent acquisition add execution uncertainty, while the article presents the overall case as an opportunistic, income-focused investment thesis.

Analysis

The key risk is not whether these brands survive, but whether they can defend unit volumes and margins without training consumers to trade down. Private-label gains can persist after inflation eases, limiting the pricing reset that dividend bulls may be underwriting. With cash yields above 4%, these equities also need credible earnings and dividend growth—not simply elevated starting yields—to compete for income capital; a stable payout can coexist with weak total returns if multiples compress.

The names have different risk profiles. PEP’s category and geographic breadth makes it the most defensible exposure, but broad diversification does not insulate it from health-oriented substitution or value-seeking shoppers. HRL’s foundation ownership may support dividend continuity, while concentrated ownership also reduces the prospect of a takeover or activist catalyst. MKC’s proposed Unilever food-business acquisition is the largest underwriting variable: scale may improve reach, but financing, integration, and any dilution or leverage burden matter more than the headline increase in business size. For CLX, separate acquisition-driven reported growth from organic demand; the cited outlook is management guidance, not proof of a margin recovery.

Over days, yield screens may attract income buyers, but rates and weak volume commentary can overwhelm that support. Over 1–3 months, watch quarterly volume/mix, gross-margin trajectory, and revisions to organic growth; for MKC, verify transaction terms, funding, and pro forma leverage. Over 6–18 months, sustained private-label share or repeated price/volume trade-offs would challenge the dividend-growth case. The contrarian point: long dividend records are evidence of resilience, not a valuation floor or guarantee of future increases.

Key Decisions for Investors

• Prefer a staged PEP position over buying all four as a basket: it offers the clearest relative resilience in the article, but add only if volume/mix and margin trends stabilize. Falsify the thesis on continued volume deterioration or guidance cuts.
• Do not buy MKC solely for its yield ahead of the Unilever food-business deal. Keep it on a catalyst watch until price, financing, expected synergies, and pro forma leverage are disclosed; reassess if the deal implies materially greater balance-sheet risk or dilution than expected.
• Treat CLX’s projected growth as acquisition-sensitive. Wait for reported organic growth and margin evidence before adding; a miss against its own organic outlook or renewed execution disruption would weaken the recovery case.
• HRL’s ownership structure may support payout discipline but is not a substitute for cash-flow coverage. Avoid yield-chasing until operating performance supports the dividend; monitor payout coverage and the contribution of its food-service strategy.
• Across the group, use quarterly volume, price/mix, gross margin, and dividend coverage—not yield alone—as entry signals. If long rates rise further while earnings estimates fall, expect valuation pressure even if payouts remain intact.